1-2 of 2
Shirley Wong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Sarah P. Blagden, Anne L. Hamilton, Linda Mileshkin, Shirley Wong, Agnieszka Michael, Marcia Hall, Jeffrey C. Goh, Alla S. Lisyanskaya, Michelle DeSilvio, Eleni Frangou, Euan A. Stronach, Prashanth Gopalakrishna, Tarek M. Meniawy, Hani Gabra
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (5): 1472–1478.
https://doi.org/10.1158/1078-0432.CCR-18-2277
Published: 01 March 2019
View article titled, Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Open the PDF for Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

Roberto Pili, Mark A. Rosenthal, Paul N. Mainwaring, Guy Van Hazel, Sandy Srinivas, Robert Dreicer, Sanjay Goel, Joseph Leach, Shirley Wong, Peter Clingan
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (10): 2906–2914.
https://doi.org/10.1158/1078-0432.CCR-09-3026
Published: 13 May 2010
View article titled, Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC
Open the PDF for Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC in another window